Context: Primary carnitine deficiency (PCD) is an inborn error of fatty acid metabolism. Patients with PCD are risk for sudden heart failure upon fasting or illness if they are not treated with daily Lcarnitine.
P rimary carnitine deficiency (PCD), also called carnitine transporter defect (Online Mendelian Inheritance in Man #212140), is an inborn error of fat metabolism. This autosomal-recessive disorder is caused by mutations in the SLC22A5 gene, resulting in a deficient sodiumdependent carnitine transporter (OCTN2) located in the cell membranes of the heart, skeletal muscle, kidney, lymphoblasts, and fibroblasts ( Fig. 1) (1) . This restricts the transport of carnitine into the tissues and compromises the tubular renal reuptake of carnitine, leading to a loss of carnitine in the body. Carnitine is an important cofactor for the shuttling of long-chain fatty acids into the mitochondria, where the fatty acids are metabolized through b oxidation ( Fig. 1) (1). Very low concentrations of blood free carnitine (,5 mM) indicate PCD (normal lower reference value, 21 mM) (2, 3) .
The Faroe Islands in the North Atlantic has the highest reported prevalence of PCD in the world. A nationwide screening program in the Faroe Islands established a PCD prevalence of 1:300 (3) . In Australia, the frequency of PCD is between 1:37,000 and 1:100,000 (2) . The implementation of newborn screening programs worldwide has led to identification of many more patients among both the screened children and their asymptomatic relatives (4) (5) (6) .
In infants, PCD can cause severe metabolic derangements, with hypotonia, cardiomyopathy, hypoketotic hypoglycemia, and coma or death (1, 7, 8) . Older children and adults with PCD can also present with sudden potentially fatal cardiac arrhythmia, especially when metabolic demand is increased during illness or fasting or upon treatment with carnitine-lowering drugs, such as pivalic acid antibiotics (2, 9, 10) . In addition to this, some patients present with myopathy and some report that they are more easily fatigued than others (3, 11) , although many patients exhibit no or only very mild symptoms (12) (13) (14) (15) .
Skeletal muscle is strongly dependent on fat metabolism to generate energy for muscle work. However, little is known about skeletal muscle metabolism in PCD, and symptoms of exercise intolerance have never been systematically documented. Research has focused on characterization and treatment of the cardiac manifestations because of the severe nature of these symptoms. However, effects on skeletal muscle could be overlooked as a feature in this growing group of patients.
Daily intake of L-carnitine is thought to prevent potentially fatal cardiac arrhythmias and cardiomyopathy (7, 8, 16) . Supplementation with daily oral L-carnitine is advised in all patients with PCD to maintain plasma carnitine concentration in accordance with regular blood carnitine measurements (17) .
In this study, we therefore investigated skeletal muscle fat and carbohydrate Figure 1 . The role of the plasma membrane sodium-dependent carnitine transporter (OCTN2) in muscle tissue (A) and the kidneys (B). (A) Carnitine is cotransported with Na+ into the cytosol through the OCTN2. Long-chain fatty acids (LCFA) pass the plasma membrane passively. The carnitine-palmitoyl transporter I (CPTI) couples carnitine to the LCFA, creating long-chain acyl-carnitines (LC-acyl-carnitine), which are transported across the inner mitochondrial membrane by the carnitine-acylcarnitine translocase (CACT) in exchange with carnitine. The carnitine-palmitoyl transporter II (CPTII) uncouples the LC-acyls from carnitine and the LC-acyls couples to coenzyme A (CoA) and proceeds to b-oxidation in the mitochondrial matrix. (B) Carnitine and acyl-carnitines passing through the kidneys undergo glomerular filtration, but a substantial amount of carnitine is taken up again by OCTN2 in the apical membranes of the proximal tubular cells. metabolism during exercise in adults with PCD to determine whether L-carnitine treatment affects skeletal muscle fat metabolism. We did this by increasing the demand for fat oxidation during sub-maximal-intensity exercise of longer duration while measuring fat and carbohydrate metabolism with indirect calorimetry and stable isotope technique.
Materials and Methods

Participants
All known patients homozygous for the c.95A.G (p.N32S) mutation younger than 80 years in the Faroe Islands were invited by letter to participate (Fig. 2) . Eight Faroese patients with PCD (one woman and seven men; age range, 18 to 45 years) were included (Table 1) . One patient was diagnosed soon after birth when he presented as a "floppy infant" with metabolic decompensation and a blood sample showed low carnitine concentration. Another patient was diagnosed because a relative had been diagnosed with PCD. The remaining six patients were identified through the national PCD screening program on the Faroe Islands in 2009-2010. All patients were asymptomatic at the time of the trial. Apart from the one patient who was diagnosed in infancy, the other participating patients had no history of metabolic crises or cardiac symptoms. All had taken daily L-carnitine supplement for $3 years at individual doses ranging from 50 to 150 mg 3 kg 21 3 day
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, individually adjusted to keep total free carnitine in blood at a concentration . 20 mM in accordance with regular blood measurements.
Six of the seven patients who were diagnosed as adolescents or adults reported that they had felt an improvement in physical endurance with L-carnitine treatment. A group of 10 healthy, untrained control participants (three women and seven men) was included. They have also contributed with control data for another study (18) and were selected for this study because they matched the age and sex of the patients with PCD and had completed the same exercise protocol. The healthy controls performed all tests at the Copenhagen Neuromuscular Center, Copenhagen, Denmark, and the patients did so at the National Hospital in Tórshavn, Faroe Islands.
Experimental design
Pre-experimental exercise testing
To determine maximal oxygen uptake (VO 2max ) and maximal workload, all participants performed an incremental exercise test to exhaustion on an upright cycle ergometer (patients: eBike Comfort, GE Healthcare, Wauwatosa, WI; healthy controls: 939E, Monark, Vansbro, Sweden). Gas exchange was measured with a metabolic cart (both groups: Cosmed Quark b2; Cosmed Srl., Milan, Italy). Participants evaluated their rate of perceived exertion on a Borg scale.
Substrate turnover studies
The following morning, patients met at the laboratory after having fasted overnight. One venous catheter was inserted in a cubital vein for the infusion of stable isotope tracers, and another was inserted in the distal cephalic vein for drawing blood samples. A heating pad, covering the hand and distal forearm, ensured shunting of arterial blood to the veins to obtain arterialized blood (19 After 2 hours of rest, participants performed a submaximal exercise test on the ergometer for 60 minutes. Workload was set to correspond to 60% of VO 2max . At this work intensity, lipolysis and fat oxidation rates are high. Total fatty-acid oxidation and carbohydrate oxidation rates were measured with indirect calorimetry. At the onset of exercise, the infusion rate of stabile isotope tracers was doubled. Blood samples were drawn before the infusions and every 10 minutes, from 20 minutes before exercise, until the end of exercise. At the same time points, expired air was collected in a 15-L Douglas bag (Hans Rudolph, Kansas City, MO) and 10-mL samples were transferred to vacuum tubes (Vacutainer, BD, Franklin Lakes, NJ) for 13 CO 2 analysis. All patients repeated this substrate turnover study after 4 days without L-carnitine treatment.
Discontinuation of L-carnitine treatment
For 4 days, patients paused L-carnitine treatment. The duration was chosen to ensure that the carnitine from the treatment had been washed out [case reports have suggested that this takes 2 to 3 days (20) ] and that the stable isotope tracers from the first substrate turnover study had been washed out before the second study (21) . We estimated that both these criteria were fulfilled with 4 days of treatment discontinuation without exposing patients to an unnecessarily long period with the risk for cardiac complications. Once the last substrate turnover study had been conducted, patients resumed their daily oral L-carnitine supplement. Patients were kept hospitalized for 24 hours after resuming the L-carnitine supplementation. The kinetics of L-carnitine during the 4 days of pausing the treatment has been reported elsewhere (22) .
Safety measures
While L-carnitine was paused, the patients were admitted to the Department of Internal Medicine at the National Hospital of the Faroe Islands for continuous monitoring with cardiac telemetry. Echocardiography was performed in all patients to exclude signs of cardiomyopathy before treatment discontinuation. Plasma creatine kinase (CK) concentrations were measured before and after 4 days of treatment as an indicator of muscle damage.
Preparation of stable isotope tracers
The priming dose of Na 13 HCO 3 (0.085 mg 3 kg
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) and 2 H 2 -D-glucose (2.44 mg 3 kg
) was dissolved in isotonic saline and passed through a 0.2-mm antibacterial filter into a sterile syringe. [U-
13 C]-palmitate (99% enriched; Cambridge Isotope Laboratories, Andover, MA) was dissolved in warm (60°C), sterile water; passed through a 0.2-mm antibacterial filter; and mixed with a 5% human albumin solution.
Blood sample analyses
During the substrate turnover studies, blood samples were drawn for analyses of metabolites and hormones. They were transferred to cooled tubes with EDTA (0.33 M, 10 mL 3 mL
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) and spun at 4000 rpm for 10 minutes. Plasma was distributed to Eppendorf tubes and immediately frozen on dry ice and stored at 280°C until analysis. Plasma insulin analyses were performed at the Department of Clinical Biochemistry at Righospitalet, Copenhagen, Denmark (Cobas 8000, Roche, Rotkreuz, Switzerland). Plasma free fatty acids and epinephrine were analyzed by spectrophotometry (Multiskan GO, SkanIt™ Software; ThermoFisher Scientific Inc., Waltham, MA). Plasma palmitate and 13 CO 2 -breath enrichment was analyzed by gas chromatography isotope ratio-mass spectrometry (Thermo Finnigan MAT GmbH, Bremen, Germany). Isotope tracer enrichments were determined by using gas chromatography-mass spectrometry (Thermo Finnigan MAT GmbH).
Muscle biopsies
Muscle needle biopsy specimens were taken from all patients and healthy controls. The biopsy specimens (5-mm Bergström needle) were taken from lateral vastus muscle within 1 hour after the substrate turnover studies. Muscle samples were immediately frozen in liquid nitrogen and stored until analyses for carnitine and acyl-carnitine concentrations. In addition, samples from four patients were frozen in isopentane, cut, and stained with red-oil-O for histologic examination.
Carnitine and acyl-carnitine analyses
Carnitine and acyl-carnitine concentrations were measured in plasma and muscle before and after 4 days of L-carnitine discontinuation. Samples were analyzed by using ultra-performance liquid chromatography-tandem mass spectrometry, as previously described (18) .
Calculations
Total fat and carbohydrate oxidation was calculated by using a nonprotein respiratory quotient (23) . The Steele non-steady-state equation for stable isotopes was used to calculate palmitate rate of appearance and disappearance (24) . The whole-body palmitate rate of oxidation was calculated by using an acetate correction factor for similar work intensities (25) .
Statistics
Differences within a group between rest and exercise and between on and off treatment were addressed with a Student paired t test. Differences between groups were assessed with a Student t test. A P value , 0.05 was considered to indicate a statistically significant difference (two-tailed testing). Values are reported as means 6 SD. The 95% CIs are reported for differences in means.
Study approval and registration
Research ethical approval for Denmark and the Faroe Islands was obtained (approval number H-1-2012-130 with the Regional Committee on Biomedical Research Ethics of Copenhagen). The study was conducted in accordance with the Declaration of Helsinki principles. All participants gave written informed consent before inclusion in the study.
Results
Maximal exercise
All patients completed an incremental exercise test to exhaustion, and VO 2max and maximal workloads were similar to those in healthy controls. Male  21  56  3793  205  100  Patient 2  19  Male  30  37  3770  255  110  Patient 3  28  Male  26  49  4294  330  150  Patient 4  20  Male  26  40  3513  330  100  Patient 5  50  Male  27  43  2443  315  120  Patient 6  26  Male  37  29  3948  285  100  Patient 7  18  Female  26  26  2047  150 
Values expressed with plus/minus sign are 6 SD.
Abbreviations: W max , maximal workload; W submax , submaximal workload. a P , 0.05 vs healthy controls.
Submaximal exercise
Patients and healthy controls worked at similar absolute workloads (Table 1 ). In accordance with this, there was no significant difference in submaximal work relative to maximal workload (40% 6 6% in patients vs 42% 6 4% in controls; P = 0.573), to maximal heart rate (71% 6 8% in patients vs 75% 6 4% in controls, P = 0.222) or to VO 2max (58% 6 11% in patients vs 61% 6 5% in controls; P = 0.491). The patients' heart rate and oxygen uptake during submaximal exercise were almost identical on and off L-carnitine treatment (132 6 17 vs 132 6 13 beats/min and 1968 6 301 vs 1920 6 296 mL 3 kg 21 , respectively; P = 0.843). Patients and healthy controls scored the same level of perceived exertion during exercise (14 6 3 in patients vs 15 6 3 in controls; P = 0.307).
Substrate turnover studies
Total fatty acid oxidation at rest was the same in patients with PCD and healthy controls irrespective of L-carnitine treatment (Fig. 3) . During L-carnitine treatment, total fatty acid oxidation at submaximal exercise was lower in patients with PCD than in healthy controls (P , 0.001). Without L-carnitine treatment, total fatty acid oxidation during exercise was impaired and was significantly lower than with treatment (P = 0.008) (Fig. 3) . Palmitate oxidation rate during exercise off and on carnitine treatment paralleled findings for total fatty acid oxidation. In fact, without treatment palmitate oxidation did not increase from rest (P = 0.539). Total carbohydrate oxidation in patients with PCD during exercise was higher without than with L-carnitine treatment (mean difference, 
Metabolites and hormones
Plasma free fatty acid concentrations at rest were higher in patients with L-carnitine treatment than in healthy controls (P = 0.014), but during exercise there was no difference (P = 0.143 with L-carnitine and P = 0.151 without) ( Table 2 ). Plasma insulin concentrations at rest were higher in patients, both at rest and during exercise, irrespective of treatment (P , 0.001). During exercise, insulin levels dropped in all studied groups and there was no difference between patients with and without L-carnitine treatment (P = 0.065). Epinephrine concentrations increased similarly in all groups during exercise.
Plasma and muscle carnitine
On L-carnitine treatment, plasma carnitine concentrations were similar in patients and healthy controls (Fig. 4) . After 4 days off treatment, carnitine concentrations in plasma dropped to 21% 6 9% of treatment levels in patients (P , 0.001). Muscle carnitine concentrations were 7.5% of the concentration in the controls on L-carnitine treatment (P , 0.001) and was 6.2% on the fourth day off treatment (P , 0.001).
Safety measures
Echocardiography showed slight signs of left ventricular hypertrophy in one patient, which was deemed clinically insignificant by a cardiologist. No cardiac events or abnormalities on electrocardiograms occurred during the 4 days off treatment. One patient had an elevated CK level of 655 U/L on treatment and 425 U/L off. CK concentrations for all other patients were below the reference value of 300 mM.
Muscle histology
The muscle biopsy specimens showed no signs of myopathy (Fig. 5) . In two of the four patients, red-oil-O staining showed increased amounts of lipid droplets (patients 7 and 5). Biopsy specimens from the two others appeared normal (patients 8 and 6). There was no change after discontinuation of L-carnitine treatment.
Discussion
The main findings were that patients with PCD have an impaired capacity for oxidation of long-chain fatty acids during exercise and that this deficiency can be partially restored by L-carnitine supplementation. With short-term L-carnitine discontinuation, we have shown that in patients with PCD, the impaired transport of long-chain fatty acids across the inner mitochondrial membrane and adhering carnitine deficiency affects their rate of b-oxidation, thereby affecting cellular metabolism and energy production in muscle. This shows that the condition not only can have serious impact on cardiac function but also affects muscle energy metabolism. Our study also showed that L-carnitine treatment in a disorder of fatty acid oxidation positively affects intermediary metabolism. The limitation of fat combustion during exercise is likely clinically meaningful for endurance because patients diagnosed after childhood all reported reduced stamina and increased fatigability before starting L-carnitine treatment. These findings of impaired fat oxidation and upregulated carbohydrate oxidation in PCD are in line with studies in patients with other inborn errors of fat metabolism (18) . So, from this perspective, PCD is a typical, albeit mild, metabolic myopathy. Although the patients endured the exercise of the same intensity and duration as the healthy controls, our results show that moderate-intensity exercise is enough to reveal the limitation in fatty acid oxidation without the presence of other metabolic stressors, such as fever or fasting.
We have previously shown that fatty acid oxidation is nearly blocked during exercise and that prolonged exercise triggers symptoms of exercise intolerance in patients with other inborn errors of fat metabolism (carnitine palmitoyltransferase II deficiency, very longchain acyl-CoA dehydrogenase deficiency, and neutral lipid storage disease (26) (27) (28) . Unlike patients with those conditions, patients with PCD can mobilize and oxidize fat to some extent and do not show acute symptoms of exercise intolerance. Although the main reason to treat patients with PCD using L-carnitine supplementation is to prevent especially severe cardiac arrhythmia and metabolic crises, supplementation provides an evident benefit to muscle fat metabolism; this benefit is also indicated by the participating patients reporting improved endurance and less fatigue after receiving Lcarnitine.
Both total fatty acid and palmitate oxidation rates were higher with long-term L-carnitine treatment than without the treatment. Although the total fatty acid oxidation during exercise was higher with treatment in all patients, it still did not reach the values of the healthy controls. To compensate for the lower fat oxidation, both on and off L-carnitine treatment, the patients were more dependent on carbohydrate oxidation to fuel the exercise. The positive effect of long-term L-carnitine on muscle fat metabolism is in line with the patients reporting less fatigue on treatment.
Cardiac muscle, like skeletal muscle, is striated, and contractions are fueled primarily by oxidation of fat in both types of muscle. It is therefore likely that cardiac muscle metabolism meets the same limitations as we have now demonstrated in skeletal muscle when carnitine stores are depleted and energy demand is increased. The cause of sudden cardiac death in PCD is unknown, but our findings suggest that limitations in energy metabolism play a role in the pathophysiology of the cardiac manifestations in PCD. With L-carnitine treatment, the same improvement in fat metabolism likely takes place in cardiac muscle and contributes to the prevention of cardiac arrhythmia and cardiomyopathy in patients. Also, the supplied L-carnitine ensures removal of potentially toxic acyl-carnitine intermediates (29) .
All reported deaths related to PCD on the Faroe Islands have occurred among patients homozygous for the c.95A.G (p.N32S) like the patients studied here, and among patients who have been shown to have very low residual OCTN2 activity and blood carnitine concentrations , 5 mM in dried blood spot samples. The highest risk for cardiac events is associated with the mutations causing the lowest OCTN2 activity (30) . It can therefore be debated whether daily high-dose Lcarnitine treatment is strictly necessary for all adults with PCD. Some patients with other mutations can have slightly higher carnitine levels of 5 to 7 mM in dried blood spots and a higher OCTN2 activity (3). It would be interesting to know whether skeletal muscle metabolism is affected to the same degree in these patients or if skeletal muscle responds to L-carnitine treatment in the same way.
L-Carnitine is widely used as a treatment of conditions associated with secondary carnitine deficiency and has also been studied extensively as a potential "fat burner" in healthy persons (31, 32) . It is often prescribed to patients according to the argument that a lack of carnitine limits fat oxidation, although evidence for this is lacking (33) . Our study demonstrates such an effect of L-carnitine treatment in patients. Patients with mediumchain acyl-CoA dehydrogenase (MCAD) deficiency have secondary carnitine deficiency and limited fat oxidation during exercise, but this is not altered by L-carnitine treatment, unlike in the patients with PCD (18) . In MCAD deficiency, plasma carnitine concentrations are only moderately decreased to~8 to 15 mM, whereas in PCD, plasma concentrations are , 8 mM (Fig. 4) . Most important, patients with MCAD have an intact carnitine transporter, securing a higher intramuscular carnitine concentration despite low plasma carnitine. It appears that secondary carnitine deficiency is an effect of, rather than causative for, compromised fatty acid oxidation (11, 18) . Based on existing evidence, it is likely that in patients with an intact carnitine transporter, plasma carnitine concentrations must be extremely low to act as a limiting factor for fatty acid metabolism.
We found that plasma carnitine concentrations were markedly higher with L-carnitine supplementation and did not differ significantly from concentrations in healthy controls, whereas the intramuscular concentrations were extremely low and only tended to increase with treatment (Fig. 4) (22) . Still, there was a clear positive effect on skeletal muscle fat metabolism. With the current aggressive treatment regimen, a high concentration of acyl-carnitines is found in blood and urine (22) . Acylcarnitines originate from the intracellular coupling of carnitine to fatty acids (Fig. 1) , so their presence in blood and urine indicate that the supplemented L-carnitine does reach the cytosol; however, the increase in intracellular free carnitine is hardly measurable (34) . Our findings are in line with fibroblast studies showing that small increases in intracellular carnitine concentration (from 2% to 5% of those in healthy persons) are enough to increase fat oxidation (20) .
It remains to be investigated whether higher doses of Lcarnitine can increase skeletal muscle fat metabolism even further. Our patients are now taking up to 20 tablets daily, and more would be challenging to ingest. Initially, it could be interesting to explore whether the carnitine transporters are already fully loaded and whether lower L-carnitine doses can improve skeletal muscle fat oxidation without compromising the prevention of cardiac complications, which should remain as the primary treatment target.
We have now studied the effect of short-term discontinuation of long-term treatment with L-carnitine. For comparison, it would be interesting to study newly diagnosed patients before they receive treatment and to study how long it takes for the skeletal muscles to respond to treatment or to determine whether the fat metabolism differs between patients who have never received L-carnitine and those with only 4 days' discontinuation.
Since the implementation of newborn screening programs, the group of patients with PCD has grown, as has the number of clinicians faced with the challenge of deciding on a treatment strategy for children and their adult relatives without symptoms.
This study provides evidence that skeletal muscle metabolism is limited by PCD even in clinically very mildly affected patients, and that skeletal muscle fat metabolism decreases with short-term discontinuation of L-carnitine treatment. This suggests that focus on identifying and treating patients with PCD at risk for developing serious cardiac complications should include L-carnitine treatment not only to prevent cardiac events but also to boost fat oxidation capacity in skeletal muscle during exercise, and potentially during other situations with need for increased fat oxidation, such as mental stress, cold shivering, fever, and fasting.
